{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 21 of 61', 'Medtronic', '8. Selection of Subjects', '8.1. Study Population', 'The intended study population is subjects diagnosed with OAB and associated signs and symptoms of', 'UUI.', '8.2. Subject Enrollment', 'Subjects are considered enrolled at the time the study-specific ICF is signed. Each subject must meet all', 'the inclusion criteria and no exclusion criteria to be eligible to participate in this study. Any subject not', 'meeting eligibility criteria will be excluded from study participation. Site personnel must complete logs', 'related to recruitment and enrollment as required by the study.', '8.3. Inclusion Criteria', 'To be eligible to participate in the study, a subject must meet all the following inclusion criteria:', '1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3-day baseline', 'voiding diary demonstrating at least 3 UUI episodes', '2. Female subjects 18 years of age or older', '3. Candidate for InterStim Lead Placement', '4. Willing and able to accurately complete voiding diaries, questionnaires, attend visits, and', 'comply with the study protocol (which includes maintenance of InterStim II programming', 'settings over the course of the study)', '5. Willing and able to provide signed and dated informed consent', '6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder (OAB)', 'medication', '8.4 Exclusion Criteria', 'A potential subject who meets any of the following criteria will be excluded from participating in the', 'study:', '1. Have neurological conditions such as multiple sclerosis, clinically significant peripheral', 'neuropathy or spinal cord injury', '2. History of diabetes unless the diabetes is well-controlled through diet and/or medications', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 22 of 61', 'Medtronic', '3. Symptomatic urinary tract infection (UTI)', '4. Have primary stress incontinence or mixed incontinence where the stress component overrides', 'the urge component', '5.', 'Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have', 'botulinum toxin treatment during the study', '6. Implanted with a neurostimulator, pacemaker, or defibrillator', '7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic', 'exposure, or RF energy exposure not included within the scanning conditions provided with the', 'MRI Guidelines for InterStim Therapy', '8. Women who are pregnant or planning to become pregnant', '9. Characteristics indicating a poor understanding of the study or characteristics that indicate the', 'subject may have poor compliance with the study protocol requirements', '10. Currently enrolled or planning to enroll in a potentially confounding clinical study during the', 'course of the study (co-enrollment in concurrent studies is only allowed when documented pre-', 'approval is obtained from the Medtronic Study Manager (or designee)', '9. Study Procedures', 'The study schedule, procedures, and methods of assessment are defined in detail to enable compliance', 'with the required activities, and to ensure that the resulting data meet the criteria for evaluability. See', 'Figure 9-1 for Study Visit. Electronic case report forms (eCRF) will be provided for use in collecting data', 'for all subjects; the pertinent eCRFs along with the applicable source documentation will be completed', 'for each subject.', 'The following study visits will be conducted:', '1. Enrollment/Baseline', '2. Tined Lead or temporary Test Stimulation Lead Implant', '3. Therapy Evaluation', '4. Tined Lead (if applicable) / Neurostimulator Device Implant (randomization procedures)', '5. One Week Follow-up Visit', '6. Six Week Follow-up Visit', '7. Twelve Week Follow-up Visit', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 23 of 61', 'Medtronic', '9.1. Schedule of Events', 'Enrollment/Baseline', 'Subjects are considered enrolled at the time the study-specific informed consent is signed. Each subject', 'must meet all the inclusion and no exclusion criteria to be eligible to participate in the study. At the', 'enrollment/baseline visits, data will be gathered from subjects including relevant medical and', 'concomitant OAB medication history. Enrollment and Baseline Visit requirements will occur at separate', 'visits.', 'Subjects will complete the following questionnaire:', 'Overactive Bladder Symptoms Quality of Life Questionnaire (ICIQ-OABqol)', 'The voiding diary will be explained and given to the subject to be completed for 3 consecutive days. The', '3-day voiding diary must be completed along with confirmation that the subject is not pregnant or', 'planning to become pregnant during participation in the trial, as part of the assessment for study', 'eligibility.', 'Any reportable adverse events following informed consent will be documented and reported. Device', 'deficiencies will be collected beginning at the time of the first exposure to the InterStim II System.', 'Tined Lead or temporary Test Stimulation Lead Implant', 'If using basic evaluation, the temporary Test Stimulation Lead should be placed in accordance with the', 'InterStim System Test Stimulation Lead Kit and Test Stimulation Lead Technical manual.', 'If using advanced evaluation, the InterStim tined lead (model 3889) should be placed in accordance with', 'the InterStim Therapy Model 3889 Lead Implant Manual.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}